TNF and heart failure: Evidence was most robust for TNF-α inhibitors, with multiple large observational studies and meta-analyses suggesting a reduced risk of MACE compared with conventional systemic or topical therapies, despite reports of worse outcomes with high-dose TNF-α inhibition in patients with pre-existing moderate-to-severe heart failure.